Anti-parasite therapy drives changes in human visceral leishmaniasis-associated inflammatory balance

Abstract Visceral leishmaniasis (VL) remains a major public health problem worldwide. Cytokine balance is thought to play a critical role in the development of this disease. Here, we perform a prospective exploratory study addressing whether simultaneous assessment of circulating levels of different...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Théo Araújo-Santos, Bruno B. Andrade, Leonardo Gil-Santana, Nívea F. Luz, Priscila L. dos Santos, Fabrícia A. de Oliveira, Meirielly Lima Almeida, Roseane Nunes de Santana Campos, Patrícia T. Bozza, Roque P. Almeida, Valeria M. Borges
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2017
Materias:
R
Q
Acceso en línea:https://doaj.org/article/799be9b2280e4569a562fe387b5f87b2
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:799be9b2280e4569a562fe387b5f87b2
record_format dspace
spelling oai:doaj.org-article:799be9b2280e4569a562fe387b5f87b22021-12-02T15:18:52ZAnti-parasite therapy drives changes in human visceral leishmaniasis-associated inflammatory balance10.1038/s41598-017-04595-82045-2322https://doaj.org/article/799be9b2280e4569a562fe387b5f87b22017-06-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-04595-8https://doaj.org/toc/2045-2322Abstract Visceral leishmaniasis (VL) remains a major public health problem worldwide. Cytokine balance is thought to play a critical role in the development of this disease. Here, we perform a prospective exploratory study addressing whether simultaneous assessment of circulating levels of different lipid mediators and cytokines could highlight specific pathways involved with VL pathogenesis. VL patients displayed substantial increases in serum levels of Prostaglandin F2α (PGF2α), Leukotriene B4 (LTB4), Resolvin D1 (RvD1), IL-1β, IL-6, IL-8, IL-10, IL-12p70 and TNF-α compared with uninfected endemic control group, while exhibiting decreased levels of TGF-β1. Hierarchical cluster analysis of the prospective changes in the expression level of theses parameters upon anti-Leishmania treatment initiation revealed that the inflammatory profile observed in active disease gradually changed over time and was generally reversed at day 30 of therapy. Furthermore, not only the individual concentrations of most of the inflammatory biomarkers changed upon treatment, but the correlations between those and several biochemical parameters used to characterize VL disease activity were also modified over time. These results demonstrate that an inflammatory imbalance hallmarks active VL disease and open perspective for manipulation of these pathways in future studies examining a potential host-directed therapy against VL.Théo Araújo-SantosBruno B. AndradeLeonardo Gil-SantanaNívea F. LuzPriscila L. dos SantosFabrícia A. de OliveiraMeirielly Lima AlmeidaRoseane Nunes de Santana CamposPatrícia T. BozzaRoque P. AlmeidaValeria M. BorgesNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-8 (2017)
institution DOAJ
collection DOAJ
language EN
topic Medicine
R
Science
Q
spellingShingle Medicine
R
Science
Q
Théo Araújo-Santos
Bruno B. Andrade
Leonardo Gil-Santana
Nívea F. Luz
Priscila L. dos Santos
Fabrícia A. de Oliveira
Meirielly Lima Almeida
Roseane Nunes de Santana Campos
Patrícia T. Bozza
Roque P. Almeida
Valeria M. Borges
Anti-parasite therapy drives changes in human visceral leishmaniasis-associated inflammatory balance
description Abstract Visceral leishmaniasis (VL) remains a major public health problem worldwide. Cytokine balance is thought to play a critical role in the development of this disease. Here, we perform a prospective exploratory study addressing whether simultaneous assessment of circulating levels of different lipid mediators and cytokines could highlight specific pathways involved with VL pathogenesis. VL patients displayed substantial increases in serum levels of Prostaglandin F2α (PGF2α), Leukotriene B4 (LTB4), Resolvin D1 (RvD1), IL-1β, IL-6, IL-8, IL-10, IL-12p70 and TNF-α compared with uninfected endemic control group, while exhibiting decreased levels of TGF-β1. Hierarchical cluster analysis of the prospective changes in the expression level of theses parameters upon anti-Leishmania treatment initiation revealed that the inflammatory profile observed in active disease gradually changed over time and was generally reversed at day 30 of therapy. Furthermore, not only the individual concentrations of most of the inflammatory biomarkers changed upon treatment, but the correlations between those and several biochemical parameters used to characterize VL disease activity were also modified over time. These results demonstrate that an inflammatory imbalance hallmarks active VL disease and open perspective for manipulation of these pathways in future studies examining a potential host-directed therapy against VL.
format article
author Théo Araújo-Santos
Bruno B. Andrade
Leonardo Gil-Santana
Nívea F. Luz
Priscila L. dos Santos
Fabrícia A. de Oliveira
Meirielly Lima Almeida
Roseane Nunes de Santana Campos
Patrícia T. Bozza
Roque P. Almeida
Valeria M. Borges
author_facet Théo Araújo-Santos
Bruno B. Andrade
Leonardo Gil-Santana
Nívea F. Luz
Priscila L. dos Santos
Fabrícia A. de Oliveira
Meirielly Lima Almeida
Roseane Nunes de Santana Campos
Patrícia T. Bozza
Roque P. Almeida
Valeria M. Borges
author_sort Théo Araújo-Santos
title Anti-parasite therapy drives changes in human visceral leishmaniasis-associated inflammatory balance
title_short Anti-parasite therapy drives changes in human visceral leishmaniasis-associated inflammatory balance
title_full Anti-parasite therapy drives changes in human visceral leishmaniasis-associated inflammatory balance
title_fullStr Anti-parasite therapy drives changes in human visceral leishmaniasis-associated inflammatory balance
title_full_unstemmed Anti-parasite therapy drives changes in human visceral leishmaniasis-associated inflammatory balance
title_sort anti-parasite therapy drives changes in human visceral leishmaniasis-associated inflammatory balance
publisher Nature Portfolio
publishDate 2017
url https://doaj.org/article/799be9b2280e4569a562fe387b5f87b2
work_keys_str_mv AT theoaraujosantos antiparasitetherapydriveschangesinhumanvisceralleishmaniasisassociatedinflammatorybalance
AT brunobandrade antiparasitetherapydriveschangesinhumanvisceralleishmaniasisassociatedinflammatorybalance
AT leonardogilsantana antiparasitetherapydriveschangesinhumanvisceralleishmaniasisassociatedinflammatorybalance
AT niveafluz antiparasitetherapydriveschangesinhumanvisceralleishmaniasisassociatedinflammatorybalance
AT priscilaldossantos antiparasitetherapydriveschangesinhumanvisceralleishmaniasisassociatedinflammatorybalance
AT fabriciaadeoliveira antiparasitetherapydriveschangesinhumanvisceralleishmaniasisassociatedinflammatorybalance
AT meiriellylimaalmeida antiparasitetherapydriveschangesinhumanvisceralleishmaniasisassociatedinflammatorybalance
AT roseanenunesdesantanacampos antiparasitetherapydriveschangesinhumanvisceralleishmaniasisassociatedinflammatorybalance
AT patriciatbozza antiparasitetherapydriveschangesinhumanvisceralleishmaniasisassociatedinflammatorybalance
AT roquepalmeida antiparasitetherapydriveschangesinhumanvisceralleishmaniasisassociatedinflammatorybalance
AT valeriamborges antiparasitetherapydriveschangesinhumanvisceralleishmaniasisassociatedinflammatorybalance
_version_ 1718387453898784768